Covovax
- All
- News
- Videos
-
Current Covid Strain Mild, 5-6 Million Covovax Doses Made: Adar Poonawalla
- Saturday April 22, 2023
- India News | Press Trust of India
The prevalent strain of COVID-19 is mild and the Serum Institute of India (SII) has already produced five to six million doses of the Covovax vaccine, said the company's chief executive officer Adar Poonawalla.
- www.ndtv.com
-
Covovax Booster Dose To Be Available On CoWIN, Cost Rs 225: Report
- Monday April 10, 2023
- India News | Press Trust of India
Union Health Minister Mansukh Mandaviya is learnt to have approved the inclusion of Serum Institute's Covovax on the CoWIN portal as a heterologous booster dose for adults, official sources said on Monday.
- www.ndtv.com
-
Serum Institute Seeks Inclusion Of Covovax On CoWIN As Booster Dose For Adults
- Monday April 3, 2023
- India News | Press Trust of India
The DCGI approved Covovax for restricted use in emergency situations in adults on December 28, 2021, in the 12-17 age group on March 9, 2022, and in the 7-11 age group on June 28, 2022, subject to certain conditions.
- www.ndtv.com
-
China Needs "Good Covid Booster" Like Covovax, Says Adar Poonawalla
- Thursday January 26, 2023
- India News | Asian News International
China needs a good COVID-19 booster vaccine like Covovax, but so far there hasn't been a positive response from China, said Chief Executive Officer of Serum Institute of India (SII), Adar Poonawalla on Wednesday.
- www.ndtv.com
-
Serum Institute Seeks Inclusion Of Covid Jab 'Covovax' In CoWIN Portal
- Wednesday January 18, 2023
- India News | Press Trust of India
Serum Institute of India has written to the Union Health Ministry seeking the inclusion of its Covid vaccine Covovax in the CoWIN portal as a heterologous booster dose for adults, official sources said on Wednesday.
- www.ndtv.com
-
Exclusive: "Telling China To Take Our Booster," Adar Poonawalla Tells NDTV
- Tuesday January 17, 2023
- India News | Reported by Vishnu Som
The Serum Institute of India is working to market its two key vaccines for Covid -- Covovax and Covishield -- in China, which is seeing a resurgence of the pandemic.
- www.ndtv.com
-
Centre's Panel Recommends Market Clearance To Covovax As Covid Booster: Report
- Thursday January 12, 2023
- India News | Press Trust of India
An expert panel of the central drug regulatory authority has recommended market authorisation for Serum Institute of India's Covid vaccine Covovax as a heterologous booster dose for adults, Press Trust of India reported.
- www.ndtv.com
-
Covovax To Get Approval As Covid Booster In 10-15 Days: Adar Poonawalla
- Sunday January 8, 2023
- India News | Press Trust of India
Serum Institute of India chief executive officer Adar Poonawalla on Sunday said its Covovax vaccine will get approval as a booster in the next 10 to 15 days, adding it works well against the Omicron variant of coronavirus.
- www.ndtv.com
-
Serum Institute's Covid Vaccine Covovax Cleared For 7-11 Age Group
- Wednesday June 29, 2022
- India News | Press Trust of India
The Drugs Controller General of India (DCGI) on Tuesday approved Serum Institute's COVID-19 vaccine Covovax for restricted emergency use in children aged 7 to 11 years subject to certain conditions, official sources said.
- www.ndtv.com
-
"Covovax Available For Everyone Above 12 Years", Tweets Adar Poonawalla
- Thursday May 5, 2022
- India News | Asian News International
Chief Executive Officer of Pune based Serum Institute of India Adar Poonawalla on Wednesday clarified that the COVID-19 vaccine Covovax is available for everyone above the age of 12 years.
- www.ndtv.com
-
Covovax Vaccine Now Available For 12-17 Age Group At Private Centres
- Monday May 2, 2022
- India News | Press Trust of India
Children aged 12 to 17 years can now get the Serum Institute's coronavirus vaccine Covovax at private centres with a provision for it being made on the CoWIN portal, official sources said on Monday.
- www.ndtv.com
-
Immunisation Panel Approves Covovax Vaccine For 12-17 Age Group: Report
- Friday April 29, 2022
- India News | Asian News International
National Technical Advisory Group on Immunisation (NTAGI) on Friday approved Serum Institute of India's Covovax COVID-19 vaccine for the age group 12-17, said sources.
- www.ndtv.com
-
Covovax First Indian Covid Vaccine To Be Sold In Europe: Adar Poonawalla
- Tuesday April 12, 2022
- India News | Asian News International
Serum Institute's Adar Poonawalla said Covovax is the first vaccine made in India to be sold in Europe.
- www.ndtv.com
-
Covishield Booster At Rs 600 Plus Tax: Adar Poonawalla To NDTV
- Friday April 8, 2022
- India News | Edited by Akhil Kumar
Mr Poonawala told NDTV that Covishield will cost Rs 600 plus taxes (same as before) and Covovax, once approved as a booster, will be available for Rs.900 plus taxes.
- www.ndtv.com
-
COVID-19 Working Group To Review Data For Covovax Vaccine On Friday: Report
- Wednesday March 30, 2022
- India News | Asian News International
The COVID-19 working group of the National Technical Advisory on Immunisation (NTAGI) will be reviewing the data of Serum Institute of India's vaccine - Covovax for use for children and adults, on April 1, sources said today.
- www.ndtv.com
-
Current Covid Strain Mild, 5-6 Million Covovax Doses Made: Adar Poonawalla
- Saturday April 22, 2023
- India News | Press Trust of India
The prevalent strain of COVID-19 is mild and the Serum Institute of India (SII) has already produced five to six million doses of the Covovax vaccine, said the company's chief executive officer Adar Poonawalla.
- www.ndtv.com
-
Covovax Booster Dose To Be Available On CoWIN, Cost Rs 225: Report
- Monday April 10, 2023
- India News | Press Trust of India
Union Health Minister Mansukh Mandaviya is learnt to have approved the inclusion of Serum Institute's Covovax on the CoWIN portal as a heterologous booster dose for adults, official sources said on Monday.
- www.ndtv.com
-
Serum Institute Seeks Inclusion Of Covovax On CoWIN As Booster Dose For Adults
- Monday April 3, 2023
- India News | Press Trust of India
The DCGI approved Covovax for restricted use in emergency situations in adults on December 28, 2021, in the 12-17 age group on March 9, 2022, and in the 7-11 age group on June 28, 2022, subject to certain conditions.
- www.ndtv.com
-
China Needs "Good Covid Booster" Like Covovax, Says Adar Poonawalla
- Thursday January 26, 2023
- India News | Asian News International
China needs a good COVID-19 booster vaccine like Covovax, but so far there hasn't been a positive response from China, said Chief Executive Officer of Serum Institute of India (SII), Adar Poonawalla on Wednesday.
- www.ndtv.com
-
Serum Institute Seeks Inclusion Of Covid Jab 'Covovax' In CoWIN Portal
- Wednesday January 18, 2023
- India News | Press Trust of India
Serum Institute of India has written to the Union Health Ministry seeking the inclusion of its Covid vaccine Covovax in the CoWIN portal as a heterologous booster dose for adults, official sources said on Wednesday.
- www.ndtv.com
-
Exclusive: "Telling China To Take Our Booster," Adar Poonawalla Tells NDTV
- Tuesday January 17, 2023
- India News | Reported by Vishnu Som
The Serum Institute of India is working to market its two key vaccines for Covid -- Covovax and Covishield -- in China, which is seeing a resurgence of the pandemic.
- www.ndtv.com
-
Centre's Panel Recommends Market Clearance To Covovax As Covid Booster: Report
- Thursday January 12, 2023
- India News | Press Trust of India
An expert panel of the central drug regulatory authority has recommended market authorisation for Serum Institute of India's Covid vaccine Covovax as a heterologous booster dose for adults, Press Trust of India reported.
- www.ndtv.com
-
Covovax To Get Approval As Covid Booster In 10-15 Days: Adar Poonawalla
- Sunday January 8, 2023
- India News | Press Trust of India
Serum Institute of India chief executive officer Adar Poonawalla on Sunday said its Covovax vaccine will get approval as a booster in the next 10 to 15 days, adding it works well against the Omicron variant of coronavirus.
- www.ndtv.com
-
Serum Institute's Covid Vaccine Covovax Cleared For 7-11 Age Group
- Wednesday June 29, 2022
- India News | Press Trust of India
The Drugs Controller General of India (DCGI) on Tuesday approved Serum Institute's COVID-19 vaccine Covovax for restricted emergency use in children aged 7 to 11 years subject to certain conditions, official sources said.
- www.ndtv.com
-
"Covovax Available For Everyone Above 12 Years", Tweets Adar Poonawalla
- Thursday May 5, 2022
- India News | Asian News International
Chief Executive Officer of Pune based Serum Institute of India Adar Poonawalla on Wednesday clarified that the COVID-19 vaccine Covovax is available for everyone above the age of 12 years.
- www.ndtv.com
-
Covovax Vaccine Now Available For 12-17 Age Group At Private Centres
- Monday May 2, 2022
- India News | Press Trust of India
Children aged 12 to 17 years can now get the Serum Institute's coronavirus vaccine Covovax at private centres with a provision for it being made on the CoWIN portal, official sources said on Monday.
- www.ndtv.com
-
Immunisation Panel Approves Covovax Vaccine For 12-17 Age Group: Report
- Friday April 29, 2022
- India News | Asian News International
National Technical Advisory Group on Immunisation (NTAGI) on Friday approved Serum Institute of India's Covovax COVID-19 vaccine for the age group 12-17, said sources.
- www.ndtv.com
-
Covovax First Indian Covid Vaccine To Be Sold In Europe: Adar Poonawalla
- Tuesday April 12, 2022
- India News | Asian News International
Serum Institute's Adar Poonawalla said Covovax is the first vaccine made in India to be sold in Europe.
- www.ndtv.com
-
Covishield Booster At Rs 600 Plus Tax: Adar Poonawalla To NDTV
- Friday April 8, 2022
- India News | Edited by Akhil Kumar
Mr Poonawala told NDTV that Covishield will cost Rs 600 plus taxes (same as before) and Covovax, once approved as a booster, will be available for Rs.900 plus taxes.
- www.ndtv.com
-
COVID-19 Working Group To Review Data For Covovax Vaccine On Friday: Report
- Wednesday March 30, 2022
- India News | Asian News International
The COVID-19 working group of the National Technical Advisory on Immunisation (NTAGI) will be reviewing the data of Serum Institute of India's vaccine - Covovax for use for children and adults, on April 1, sources said today.
- www.ndtv.com